Eaton Vance Management bought a new position in ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 18,650 shares of the company’s stock, valued at approximately $185,000. Eaton Vance Management owned approximately 0.07% of ZimVie at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new stake in ZimVie in the third quarter worth approximately $27,000. US Bancorp DE bought a new position in shares of ZimVie during the third quarter valued at approximately $36,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ZimVie during the third quarter valued at approximately $46,000. Strs Ohio bought a new position in shares of ZimVie during the third quarter valued at approximately $47,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of ZimVie during the third quarter valued at approximately $47,000. Hedge funds and other institutional investors own 74.29% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Barclays decreased their target price on ZimVie from $9.00 to $5.00 and set an “underweight” rating for the company in a report on Monday.
ZimVie Stock Performance
ZimVie Company Profile
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
Further Reading
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.